[A study of the correlation between the stromal reaction to the primary lesion and immunological parameters in patients with cervical cancer (author's transl)].
A correlation between the stromal reaction to the primary lesion and the clinical immunoparameters, such as, the depth of primary lesion, regional lymph node metastasis, delayed hypersensitivity reactions (DNCB, PPD and PHA skin reaction), peripheral lymphocyte count, peripheral monocyte count, peripheral lymphocyte blastogenesis to PHA and prognosis were studied in patients with cervical cancer (stage Ib, II). All patients were treated with curative operation. The degree of stromal reaction was classified to 3 groups, that is, marked stromal reaction group, moderate stromal reaction group and slight stromal reaction group and the following results were obtained. 1) There was a significant correlation between the degree of stromal reaction and the depth of primary lesion, regional lymph node metastasis (p less than 0.05). 2) The degree of stromal reaction was correlated with the positive rate of DNCB skin reaction (p less than 0.05), but there was no significant correlation between the degree of stromal reaction and the positive rate of PPD and PHA skin reaction. 3) The degree of stromal reaction was not correlated with the count of peripheral lymphocyte, monocyte and the ability of lymphocyte blastoid transformation. 4) The recurrence rate in marked stromal reaction group was 13.6%; 22.2% in moderate group and 28. 6% in slight group. There was no significant correlation in the group. 5) Five-years-survival rate in marked stromal reaction group ws 86.4%; 81.5% in moderate group and 71.4% in slight group. There was also no significant correlation in the group.
D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation; D009361:Neoplasm Invasiveness; D011379:Prognosis; D012882:Skin Tests; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology